Moderna Inc (MRNA)

[axelvento]

Yes, I think so......

personalized mRNA vaccine reduced risk of recurrence or death in melanoma.

In the cancer vaccine, the mRNA encodes for tumor-specific mutations called neoantigens. The body creates copies of these neoantigens, learns to recognize them, and creates more immune cells that can target them, therefore fighting the cancer.

The shot, when combined with Merck’s checkpoint inhibitor Keytruda, reduced the risk of cancer recurrence or death by 44% compared to Keytruda alone over a period of 1 year. It was tested in people with stage 3/4 melanoma who had their tumors removed but had a higher chance of the cancer returning due to features of their melanoma

Moderna and Merck plan to initiate a Phase 3 study in people with melanoma in 2023.

So let's see what happens with this Beast.